Reviews are mixed: early animal and small human trials show clear deltawave enhancement, while larger controlled studies have yielded inconsistent results, leaving DSIP classified as experimental Delta sleepinducing peptide Reviews
Disclosures: Maria Fernanda Raya Tonetti: Nothing to Disclose, Noemi Cabre: Nothing to Disclose, Marcos Fernandez Fondevila: Nothing to Disclose, Alvaro Eguileor: Nothing to Disclose, Bernd Schnabl: Mabwell Therapeutics: Consultant, Ambys Medicines: Consultant, Surrozen: Consultant, Nterica Bio: Stock privately held company, Axial Biotherapeutics: Grant/Research Support, Prodigy Biotech: Grant/Research Support, CymaBay Therapeutics: Grant/Research Support, Intercept Pharmaceuticals: Grant/Research Support, ChromoLogic: Grant/Research Support, Cristina Llorente: Nothing to Disclose 2633 ARBM-101 RESCUES FULMINANT WILSON DISEASE Eun-Jung Kim 1 Dasol Kim 1 Banu Akdogan 2 Mikkel Holm Vendelbo 3 Emilie Munk 4 Judith Sailer 5 Adriana Filipa Fontes 2 Jonas Engler 5 Dongsik Park 1 Hongjae Lee 1 Chunwon Jung 1 Byong-Keol Min 1 Eok Park 1 TaeWon Kim 1 Seoyoung Choi 6 So-yeon Kim 1 Alan DiSpirito 7 Thomas Sandahl 4 Weonbin Im 1 So-Young Eun 1 Hans Zischka 2 Valentina Medici 8 , 1 ARBORMED Co., Ltd., 2 Helmholtz Munich, 3 Aarhus University Hospital, 4 Aarhus University, 5 Technical University Munich, 6 ARBORMED Co., Ltd., 7 Iowa State University, 8 University of California Davis Background: Wilson disease (WD), a genetic disorder caused by disruptive mutations in the ATP7B gene, primarily manifests with copper accumulation in the liver and brain
Suzaki, Y., Fujii, Y
At Serenity Wellness and Family Practice in DeLand, our team takes a personalized approach to wellness, helping patients understand their options and make informed decisions about their health
